Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
Rhea-AI Summary
Rapport Therapeutics (NASDAQ: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in two major healthcare investor conferences in June 2025.
The company will participate in fireside chats at the Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 10:30 a.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 10:00 a.m. ET. Both presentations will be accessible via webcast on the company's investor relations website.
Positive
- None.
Negative
- None.
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences.
Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time.
Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time.
Interested parties may access the live and archived webcasts of these fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR, Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
What upcoming investor conferences will Rapport Therapeutics (RAPP) attend in June 2025?
When is Rapport Therapeutics' (RAPP) presentation at the Jefferies Global Healthcare Conference?
How can investors access Rapport Therapeutics' (RAPP) conference presentations?
What type of medicines does Rapport Therapeutics (RAPP) develop?
